FAQ: Lantern Pharma Inc. (NASDAQ: LTRN) and Its AI-Driven Oncology Innovations

What is Lantern Pharma Inc.?

Lantern Pharma Inc. is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to develop precision cancer therapies through its proprietary RADR® platform.

What is the RADR® platform?

The RADR® (Response Algorithm for Drug Positioning & Rescue) platform integrates over 200 billion oncology-specific data points to accelerate the identification and development of promising drug candidates for specific cancer types and patient subpopulations.

What types of cancer does Lantern Pharma target?

Lantern Pharma targets major oncology markets including NSCLC (non-small cell lung cancer), TNBC (triple-negative breast cancer), NHL (non-Hodgkin lymphoma), and brain and CNS cancers, including pediatric indications.

What FDA designations has Lantern Pharma received?

Lantern Pharma has received multiple FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways for its drug candidates.

How is Lantern Pharma funded?

With approximately $19.7 million in cash and equivalents, Lantern Pharma is funded through at least mid-2026 to support its pipeline advancement and platform development.

What is Starlight Therapeutics?

Starlight Therapeutics is an extension of Lantern Pharma’s efforts into brain and CNS cancers, focusing on pediatric indications supported by orphan and rare disease designations.

Where can I find more information about Lantern Pharma?

More information about Lantern Pharma can be found in the company’s newsroom at https://ibn.fm/LTRN and through its profile on InvestorBrandNetwork.

What makes Lantern Pharma’s approach unique?

Lantern Pharma’s approach is unique due to its integration of large-scale genomics, AI-based biomarker discovery, and preclinical modeling to rapidly identify and develop targeted oncology therapies, supported by its RADR® platform.